Applying Evidence to Real-world RA Management: A Case-based Approach

Applying Evidence to Real-World RA Management: A Case-Based Approach
1 AMA PRA Category 1 Credit(s)
Launch Date:
May 28, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

The intended audience for the activity is rheumatologists and other health care professionals involved in the treatment of patients with rheumatoid arthritis (RA).

Relevant Terms:

Rheumatoid arthritis, pharmacotherapies

Marc D. Cohen, MD

Marc D. Cohen, MD (Activity Chair)
Emeritus Professor of Medicine
Mayo Clinic
Adjunct Professor of Medicine
National Jewish Health
Denver, CO

Marc D. Cohen, MD, is an emeritus professor of medicine at the Mayo Clinic, a clinical professor of medicine at the University of Colorado in Denver, Colorado, and an adjunct professor of medicine of rheumatology at National Jewish Health. He attended medical school at George Washington University Medical Center in Washington, DC, and he went on to complete an internship in internal medicine at Cedars-Sinai Medical Center in Los Angeles, California. He completed a residency in internal medicine at the University of California, Los Angeles, and a fellowship in rheumatology at the Mayo Clinic in Rochester, Minnesota.
Dr. Cohen is a fellow of the Arthritis and Rheumatism Association and the American College of Physicians. Dr. Cohen was awarded "Teacher of the Year" for eleven consecutive years, as well as the "Distinguished Educator" award, and he was also the first member of the "Teacher of the Year Hall of Fame" at the Mayo Clinic in Jacksonville, where he previously worked for 22 years. He has presented at meetings and symposia around the world and authored more than 70 articles in journals such as Arthritis and Rheumatism. He was an advisory editor for Arthritis and Rheumatism and an ad hoc reviewer for many other medical journals. He has also authored numerous book chapters on rheumatology and other medical education tapes.
Dr. Cohen's particular interests are rheumatoid arthritis and systemic vasculitis. Dr. Cohen is committed to supporting investigations and endeavors, which achieve the highest level of quality in research and education. He is still actively involved in teaching rheumatology, currently at the VA Medical Center in Denver.

Jonathan Kay, MD

Jonathan Kay, MD
Professor of Medicine and Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Physician, UMass Memorial Medical Center
Worcester, MA

Jonathan Kay, MD, received his medical degree from the University of California School of Medicine in San Francisco, CA. He then completed an internship and residency at the hospital of the University of Pennsylvania in Philadelphia, PA and fellowships in rheumatology and immunology at The Brigham and Women's Hospital and Harvard Medical School in Boston, MA.

Dr. Kay is a professor of medicine at the University of Massachusetts Medical School and a physician at UMass Memorial Medical Center in Worcester, where he directs clinical research in the Division of Rheumatology.

Dr. Kay is a fellow of the American College of Rheumatology and of the American College of Physicians. He is an ad hoc reviewer for many journals and a member of the editorial boards of Arthritis Care & Research, Best Practice and Research Clinical Rheumatology, and the Journal of Clinical Rheumatology. Dr. Kay lectures internationally and is the author of more than 120 publications and book chapters.

Dr. Kay's clinical interests span the spectrum of rheumatic diseases, with special interest in rheumatoid arthritis, spondyloarthropathies, and other forms of inflammatory arthritis. He was a member of the group that developed the 2010 ACR/EULAR Diagnostic and Classification Criteria for Rheumatoid Arthritis. He chairs the Rheumatology Working Group and is a member of the Internal Medicine and Musculoskeletal Topic Advisory Groups for the World Health Organization in its revision of the International Classification of Diseases (ICD)-11.

Over the past 2 decades, his clinical research has focused on nephrogenic systemic fibrosis (formerly known as nephrogenic fibrosing dermopathy), β2-microglobulin amyloidosis, and other rheumatologic problems of patients with chronic kidney disease. He has been a principal investigator on over 50 clinical trials of novel therapies for rheumatoid arthritis, ankylosing spondylitis, gout, and osteoarthritis. Over the past several years, he has been involved in the development of biosimilars to treat rheumatic diseases.

Vibeke Strand, MD, FACP, FACR

Vibeke Strand, MD, FACP, FACR
Biopharmaceutical Consultant
Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University School of Medicine
Palo Alto, CA

Vibeke Strand, MD, is an adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine. She has been a clinical rheumatologist for more than 30 years. Dr. Strand was previously in subspecialty practice and a clinical investigator in San Francisco, and senior director of clinical research at 3 pharmaceutical/biotech companies.
Since 1991, Dr. Strand has led a consulting practice offering clinical research and regulatory strategy expertise in rheumatologic diseases to pharmaceutical and biotech companies. Over the past 20 years, she has participated in the development of all of the approved biologic agents in rheumatoid arthritis and systemic lupus erythematosus.
Dr. Strand has been an invited speaker at many FDA Arthritis Advisory Committee meetings. Since 1992, she has served as a member of the Executive Organizing Committee of Outcomes in Rheumatology Clinical Trials [OMERACT] consensus conferences. Dr. Strand is on the board and medical and scientific committee of the Northern California chapter of the Arthritis Foundation, and the scientific advisory board of CORRONA. Dr. Strand has authored over 300 publications, is a fellow of the American College of Physicians and the American College of Rheumatology, and a member of the Cosmos Club.
1. Initiate therapy in patients with high disease activity as per evidence-based guidelines pertaining to the treatment of rheumatoid arthritis to optimize therapy and improve outcomes.
2. Evaluate the current use of methotrexate as monotherapy and combination therapy, and its associated benefits and risks when treating rheumatoid arthritis.
3. Evaluate the comparative efficacy of monotherapy versus combination therapy, and the safety and tolerability of pharmacotherapies used for the management of patients with rheumatoid arthritis.
4. Re-evaluate management approaches to patients with rheumatoid arthritis who do not demonstrate an optimal response to initial therapy.

Provider Statement
This continuing medical education activity is provided by Vindico Medical Education.

Support Statement
This activity is supported by an educational grant from Genentech, Inc.

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.
Marc D. Cohen, MD
No relevant financial relationships to disclose.

Jonathan Kay, MD
Consulting Fee: Amgen, Inc., AbbVie, Inc., AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Crescendo Bioscience, Inc., Eli Lilly and Co., Epirus Biopharmaceuticals, Inc., Genentech Inc., Hospira, Inc., Janssen Biotech Inc., Merck Sharp & Dohme Corp., Nippon Kayaku Co., Novartis, Pfizer Inc., Samsung Bioepis, Roche, UCB
Contracted Research (paid to institution): AbbVie Inc., Eli Lilly and Co., Pfizer Inc., Roche

Vibeke Strand, MD, FACP, FACR
Consulting Fee: AbbVie Inc., Afferent, Adler, Amgen Inc., Ampio, Anthera, AstraZeneca, aTyr, Biogen ldec, Biotest, Bioventus, Bristol-Myers Squibb, Carbylan, Celgene, Celltrion, CORRONA, Crealta, Crescendo Bioscience Inc., Daiichi Sankyo, Eli Lilly and Co., Eupraxia, Flexion, Genentech Inc./ Roche, GlaxoSmithKline, Hospira, Idera, Incyte, Iroko, Janssen Biotech Inc, Jazz, Merck Serono, Mesoblast, Mt Tam, Novartis, Pfizer Inc., Protalex, Regeneron, Royalty, Sanofi-Genzyme, SKK, Takeda, UCB, Vertex
Advisory Board: AbbVie Inc., Amgen Inc., Biogen ldec, Bristol-Myers Squibb, Carbylan, Crealta, Crescendo Bioscience Inc., Eli Lilly and Co., Genentech, Inc./Roche, GlaxoSmithKline, Idera, Incyte, Iroko, Janssen Biotech Inc., Jazz, Merck Serono, Novartis, Pfizer Inc., Regeneron, Sanofi, Takeda UCB 

External Reviewer reports the following relationship(s):
Gregg J. Silverman, MD
No relevant financial relationships to disclose.
Vindico Medical Education staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, May 28, 2015 to May 28, 2016.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credit(s)™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA PRA Category 1 Credit(s)™. You must score a 65% or higher on the post-test to receive credit for this activity. You will have three attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Contact us:

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above


Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2015 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.